174 related articles for article (PubMed ID: 32746796)
1. Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC).
Wu X; Zhang X; Tao L; Chen P
BMC Cancer; 2020 Aug; 20(1):719. PubMed ID: 32746796
[TBL] [Abstract][Full Text] [Related]
2. The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database.
Bu X; Wang X; Wei L; Liu J; Chen M
Curr Probl Cancer; 2020 Dec; 44(6):100613. PubMed ID: 32563531
[TBL] [Abstract][Full Text] [Related]
3. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.
Giri S; Bhatt VR; Verma V; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
5. Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States.
Adjei Boakye E; Buchanan P; Hinyard L; Osazuwa-Peters N; Simpson MC; Schootman M; Piccirillo JF
Int J Cancer; 2019 Jul; 145(1):143-153. PubMed ID: 30613963
[TBL] [Abstract][Full Text] [Related]
6. The Incidence Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon and Rectal Cancer: A Population Based Study.
Guan X; Jin Y; Chen Y; Jiang Z; Liu Z; Zhao Z; Yan P; Wang G; Wang X
PLoS One; 2015; 10(11):e0143067. PubMed ID: 26571301
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
[TBL] [Abstract][Full Text] [Related]
9. Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018.
Yang Z; Liu L; Leng K; Shi G
J Gastroenterol Hepatol; 2023 Sep; 38(9):1474-1484. PubMed ID: 37114675
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
[TBL] [Abstract][Full Text] [Related]
11. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.
Jani KS; Lu SE; Murphy JD; Romesser PB; Jethwa KR; Li D; Chundury A; Wu AJ; Hathout L; Hallemeier CL; Jabbour SK
Cancer Med; 2021 Jun; 10(11):3575-3583. PubMed ID: 33960690
[TBL] [Abstract][Full Text] [Related]
12. Risk of second primary malignancy in patients with sinonasal tumors: a population-based cohort study.
Ganti A; Plitt MA; Kuan EC; Kuhar HN; Batra PS; Tajudeen BA
Int Forum Allergy Rhinol; 2018 Jun; 8(6):756-762. PubMed ID: 29381260
[TBL] [Abstract][Full Text] [Related]
13. Combined high-grade neuroendocrine carcinoma of the lung: clinicopathological and immunohistochemical study of 34 surgically resected cases.
Yamada K; Maeshima AM; Tsuta K; Tsuda H
Pathol Int; 2014 Jan; 64(1):28-33. PubMed ID: 24471967
[TBL] [Abstract][Full Text] [Related]
14. High-Grade Neuroendocrine Carcinoma with Bronchial Intraepithelial Tumor Spread: Possibly a New Histologic Feature of Large-Cell Neuroendocrine Carcinoma.
Kojima H; Watanabe R; Isaka M; Shimizu R; Kayata H; Miyata N; Maniwa T; Takahashi S; Ito I; Kameya T; Funai K; Ohde Y; Nakajima T
J Thorac Oncol; 2015 Sep; 10(9):1337-1340. PubMed ID: 26291012
[TBL] [Abstract][Full Text] [Related]
15. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.
Keegan THM; Bleyer A; Rosenberg AS; Li Q; Goldfarb M
JAMA Oncol; 2017 Nov; 3(11):1554-1557. PubMed ID: 28426850
[TBL] [Abstract][Full Text] [Related]
16. Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer.
Nelson RA; Lai LL
Cancer; 2017 Oct; 123(20):4013-4021. PubMed ID: 28608917
[TBL] [Abstract][Full Text] [Related]
17. Second Primary Malignancies of the Bones and Joints: More Common than Expected in Osteosarcoma Patients.
Freedman IG; Dowd HN; Dhodapkar MM; Halperin SJ; Grauer JN
J Am Acad Orthop Surg Glob Res Rev; 2023 Jan; 7(1):. PubMed ID: 36695170
[TBL] [Abstract][Full Text] [Related]
18. Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
Khanal A; Budhathoki N; Singh VP; Shah BK
Anticancer Res; 2017 Apr; 37(4):2033-2036. PubMed ID: 28373478
[TBL] [Abstract][Full Text] [Related]
19. Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?
Wu GX; Nelson RA; Kim JY; Raz DJ
Clin Lung Cancer; 2017 Sep; 18(5):543-550.e3. PubMed ID: 28412093
[TBL] [Abstract][Full Text] [Related]
20. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study.
Wang W
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
